Skip to main
  1. Stocks
  2. Inventiva S.A.
  3. Forecast
IVA

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva is viewed positively because lanifibranor has already shown a strong Phase 2 histology signal, with about a 19-point placebo-adjusted fibrosis benefit and a 26-point composite benefit in NATIVE, giving NATiV3 a credible foundation even under a more stringent 72-week design. The company’s Phase 3 setup looks statistically robust, as the 1,009-patient F2/F3 trial needs only about a 7-point composite and 9-point fibrosis gap to succeed, while management reported dropout below 30% and the fifth DMC recommended continuing without changes in October 2024. Fundamentally, the oral pan-PPAR mechanism, favorable F3 and diabetic enrichment, and manageable safety profile support a differentiated commercial position in MASH, especially since the company had €166.1M in cash and cash equivalents at June 30, 2026 and expects runway into 2Q2027.

Bears say

Inventiva is facing a fundamentally challenged investment case because its lead asset has already shown mixed efficacy and meaningful tolerability issues, including a missed primary endpoint in FASST and weight gain, edema, anemia, and aminotransferase elevations that can undermine long-term use. The company also faces a difficult competitive backdrop, as Rezdiffra’s benefit is described as modest and indirect while FGF21s may prove more potent, limiting lanifibranor’s differentiation beyond oral dosing. These clinical and commercial risks are compounded by explicit financing risk and the prospect that any R&D, regulatory, or commercial setback could force dilutive funding, weakening shareholder value.

Inventiva S.A. (IVA) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Inventiva S.A. (IVA) Analyst Forecast & Price Prediction

Get the latest Inventiva S.A. (IVA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Inventiva S.A. (IVA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Inventiva S.A. (IVA) has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Inventiva S.A. (IVA) Analyst Forecast & Price Prediction

Get the latest Inventiva S.A. (IVA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Inventiva S.A. (IVA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IVA stock data and trends